News
True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...
AstraZeneca PLC closed 21.60% below its 52-week high of £133.88, which the company achieved on September 3rd.
Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.
The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...
Explore more
Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...
The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...
AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...
On Monday, Clever Culture confirmed that it had received a purchase order from Novo for its flagship APAS Independence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results